Now there’s a proactive tool to screen for cancer - Galleri®
Introducing Galleri — a multi-cancer early detection blood test
The Galleri test screens for a “fingerprint” of many of the deadliest cancers before they become symptomatic, including many of those with no recommended screening tests today.1,2,3
In a large clinical study, the Galleri test screened for a signal shared by 50+ types of cancer. 3 See a list of what the Galleri test screens for.
The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. The Galleri is a screening test and does not diagnose cancer. Diagnostic testing is needed to confirm cancer. False positive and false negative results do occur. The Galleri test should be used in addition to healthcare provider recommended screening tests.
The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. The Galleri is a screening test and does not diagnose cancer. Diagnostic testing is needed to confirm cancer. False positive and false negative results do occur. The Galleri test should be used in addition to healthcare provider recommended screening tests.
Why is early detection important?
Cancer often hides, with symptoms not appearing until later stages. The earlier that cancer is diagnosed, the greater the chance of successful treatment and survival.4,5
Today, doctors test individually for 5 specific cancers — colorectal, lung (for those at risk), breast, cervical, and prostate.
While these single-cancer screenings play an important role in detecting 5 specific cancers today,* nearly 70% of cancers have no recommended screening tests.1,2*
The Galleri test identifies DNA in the bloodstream shed by cancer cells and does not predict future genetic risk for cancer. Galleri is a screening test and does not diagnose cancer. Diagnostic testing is needed to confirm cancer.
*Assumes screening is available for all prostate, breast, cervical, and colorectal cancer cases and 43% of lung cancer cases (based on the estimated proportion of lung cancers that occur in screen-eligible individuals older than 40 years).
Who is the Galleri test for?
The Galleri test is recommended for adults with an elevated risk for cancer, such as those ages 50 or older.
- The Galleri test is available by prescription only.
- Use of the Galleri test is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.
Talk to your provider about your risk for cancer, and whether the Galleri test is right for you.
Age is the biggest risk factor for cancer. People over 50 have a 13 times higher risk for cancer than those under 506 Cancer risk increases for everyone as they age, regardless of family history.6
Certain factors, in addition to age 50+, further increase cancer risk5
- Diabetes
- Obesity (BMI ≥ 30)
- Current or previous smokers
Learn how screening with Galleri has made a difference for these patients
-
Patient testimonial: Jack
Cancer Signal Detected
-
Patient testimonial: Neil
Cancer Signal Detected
-
Patient testimonial: Mike
Cancer Signal Detected
-
Patient testimonial: Rich & Staci
Cancer Signal Detected
-
Patient testimonial: Cindy
Cancer Signal Detected
-
Patient testimonial: Dave
Cancer Signal Detected
-
Patient testimonial: Jennifer
No Cancer Signal Detected
-
Patient testimonial: Jonathan
Cancer Signal Detected
-
Patient testimonial: Rich
Cancer Signal Detected
-
Patient testimonial: Cindy
Cancer Signal Detected
-
Patient testimonial: Mary and her doctor, Robert Korolevich, MD
Cancer Signal Detected
-
Patient testimonial: Roger
Cancer Signal Detected
-
Patient testimonial: Valerie
Cancer Signal Detected
-
Patient testimonial: Keith
No Cancer Signal Detected
-
Patient testimonial: Tami
No Cancer Signal Detected
How often should you take the Galleri test?
The Galleri test can be taken annually.8,9 Deadly cancers can develop at any time and progress quickly, sometimes in less than a year. Adding the Galleri test to recommended single-cancer screenings may help detect more cancers at an early stage (based on modeled data).8,9
Galleri is a test that identifies DNA shed by cancer cells and screens for cancer at the time of testing. The Galleri test is not a hereditary screening test and does not predict your future genetic risk for cancer.
The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur.
Healthy holidays!
This season, prioritize health for yourself and your loved ones by screening for multiple cancers with the Galleri test. For a limited time, receive $50 off.*
The Galleri test is available by prescription only. This offer is available through your provider or tests can be requested online at Galleri.com through an independent telemedicine provider. You must be 50 or older to take advantage of the online offer. Eligibility will be assessed at the time of your test request. The discount only applies to full-priced, self-pay tests priced at $949. Most health insurance plans do not cover the Galleri test.
Use the Galleri Key "24GIFT50" when you request the test.
Limited time offer valid only for Galleri test orders placed November 28, 2024, midnight PST through the applicable Offer End Date (defined below). Valid only for Galleri test orders requested online and approved by the GRAIL-contracted independent telemedicine provider (“Telemedicine Order”) or by your independent healthcare provider using the GRAIL-provided Test Requisition Form specifically for this offer (“Clinic Order”). The “Offer End Date” means: (i) for Telemedicine Orders, December 31, 2024, 11:59 pm PST; (ii) for Clinic Orders, January 31, 2025, 11:59 pm PST. Valid for Clinic Orders only if the blood draw for the Galleri test is completed by the applicable Offer End Date. Offer does not confirm your eligibility for the Galleri test. Valid only for one-time use on domestic US Galleri test orders only. Offer valid only for a discount off the Galleri test list price ($949). Offer cannot be: (1) combined or used with any other discount, promotion, special pricing, or payment plan; (2) used to request a credit on a test order placed prior to the offer period; or (3) posted online or on any other publicly available forum. GRAIL reserves the right to change the terms and conditions, substitute an offer of equal or greater value, and end the offer at any time without notice. For Galleri test orders requested online, you must create an account to redeem this offer and enter the code at the “Introduction” stage, where prompted.
Sign up for more information about Galleri
Resources
-
Video
Testimonial - Oncologist Perspectives
-
News
Galleri Named to TIME's Best Inventions of 2022
-
Video
Panel Discussion: The Bleeding-Edge of Early Detection
-
News
The way we approach cancer is about to change forever
-
News
A New Test for Cancer: Grounds for Optimism
The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those aged 50 or older. The Galleri test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. Galleri is intended to detect cancer signals and predict where in the body the cancer signal is located. Use of Galleri is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.
Results should be interpreted by a healthcare provider in the context of medical history, clinical signs and symptoms. A test result of No Cancer Signal Detected does not rule out cancer. A test result of Cancer Signal Detected requires confirmatory diagnostic evaluation by medically established procedures (e.g. imaging) to confirm cancer.
If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False-positive (a cancer signal detected when cancer is not present) and false-negative (a cancer signal not detected when cancer is present) test results do occur. Rx only.
The GRAIL clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists. The Galleri test was developed and its performance characteristics were determined by GRAIL. The Galleri test has not been cleared or approved by the Food and Drug Administration. The GRAIL clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is intended for clinical purposes.
- American Cancer Society. Cancer facts & figures 2022. https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2022.html [GRAIL, LLC. Data on file: GA-2021-0065]
- US Preventive Services Task Force. A,B,C grade recommendations, cancer, screenings. [cited 2023 Oct 23]. https://www.uspreventiveservicestaskforce.org/uspstf/topic_search_results
- Klein EA, Richards D, Cohn A, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021 Sep;32(9):1167-77. doi: 10.1016/j.annonc.2021.05.806
- American Cancer Society. The cancer atlas. [Internet] Early detection. https://canceratlas.cancer.org/taking-action/early-detection/
- Etzioni R, Urban N, Ramsey S, et al. The case for early detection. Nat Rev Cancer. 2003 Apr;3(4):243-52. doi: 10.1038/nrc1041
- Surveillance, Epidemiology, and End Results (SEER) Program SEER*Stat Database: Incidence - SEER Research Limited-Field Data, 21 Regs, 2020 Nov Sub (2000-2018) - Linked To County Attributes - Time Dependent (1990-2018) Income/Rurality, 1969-2019 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released 2021 Apr, based on the 2020 Nov submission. GRAIL Data on File GR-2023-0098
- American Association for Cancer Research. Cancer progress report 2023. https://cancerprogressreport.aacr.org/progress/
- Patel A. Methylated DNA biomarkers and incident cancer in the American Cancer Society (ACS) Cancer Prevention Study-3 (CPS-3) cohort. American Society of Clinical Oncology (ASCO) Annual Meeting; 2023 Jun 2-6. https://meetings.asco.org/abstracts-presentations/218486
- Sasieni P, Clarke CA, Hubbell E. Impact of MCED screening interval on reduction in late-stage cancer diagnosis and mortality. European Society for Medical Oncology (ESMO) Virtual Congress [poster]; 2021 Sep 16-21.